SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Insmed Incorporated (INSM)

NEW YORK, June 9, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Insmed Incorporated ("Insmed" or the "Company") (NASDAQ: INSM).  Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst Yael Hurwitz at [email protected] or 212-697-6484. 

The investigation concerns whether Insmed and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On June 8, 2016, post-market, Insmed revealed that it had removed its European marketing application from the European Medicines Agency ("EMA") for its lung disease drug Arikayce.  Insmed said its data from a mid-stage clinical study that was not sufficient proof for EMA approval.  Insmed said it would resubmit its application at a later time when there is more data.  Following this news, Insmed stock dropped $2.20 per share, or more than 18% to $9.80 in after-hours trading.

If you are aware of any facts relating to this investigation, or purchased shares of Insmed, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/#!insm/iz8zm or by contacting Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [email protected].  Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]

SOURCE Bronstein, Gewirtz & Grossman, LLC

Related Links

http://www.bgandg.com